Mephenesin

Mephenesin

SCHEMBL25448

Cc1ccccc1OCC(O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 1.00
KDM4E B2RXH2 3/20 1.00
LMNA P02545 5/20 0.69
AGTR1 P30556 1/20 0.69
ALOX15 P16050 1/20 0.68
KMT2A Q03164 5/20 0.64
MEN1 O00255 4/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
ADRB2 P07550 1/20 0.64
ADRB1 P08588 1/20 0.64
ADRB3 P13945 1/20 0.64
CYP2C19 P33261 2/20 0.60
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
MAPT P10636 1/20 0.59
CYP2C9 P11712 1/20 0.59
HPGD P15428 1/20 0.59
ALDH1A1 P00352 1/20 0.56
NPSR1 Q6W5P4 1/20 0.55
NPY1R P25929 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mephenesin SCHEMBL6482337 1.00 CYP1A2 (1.00) CYP1A2KDM4ELMNAAGTR1ALOX15
Mephenesin SCHEMBL29379669 1.00 CYP1A2 (1.00) CYP1A2KDM4ELMNAAGTR1ALOX15
Mephenesin SCHEMBL332864 1.00 CYP1A2 (1.00) CYP1A2KDM4ELMNAAGTR1ALOX15
Mephenesin SCHEMBL6830756 0.96 CYP1A2 (0.93) CYP1A2KDM4ELMNAAGTR1ALOX15
Mephenesin SCHEMBL8829925 0.92 CYP1A2 (0.84) CYP1A2KDM4ELMNAAGTR1ALOX15
SCHEMBL18423672 0.90 KDM4E (0.82) CYP1A2KDM4ELMNAAGTR1ALOX15
Mephenesin SCHEMBL11403767 0.88 CYP1A2 (0.77) CYP1A2KDM4ELMNAAGTR1ALOX15
SCHEMBL13328792 0.87 CYP1A2 (0.77) CYP1A2KDM4ELMNAAGTR1ALOX15
Mephenesin SCHEMBL28316204 0.87 CYP1A2 (0.75) CYP1A2KDM4ELMNAAGTR1ALOX15
SCHEMBL26326254 0.86 CYP1A2 (0.81) CYP1A2KDM4ELMNAAGTR1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3282 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702396-A1 SPECTACLE LENS FOR MANAGING MYOPIA BY MEANS OF A DUAL PROGRESSION CONTROL PROCESS Rodenstock GmbH (DE) 2026-03-04 EP claimed
US-20250313900-A1 COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS THE METHODIST HOSPITAL 2025-10-09 US claimed
EP-4623932-A1 AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA National University Corporation Chiba University (JP) 2025-10-01 EP claimed
EP-4587883-A1 REDUCING THE PROGRESSION OF MYOPIA BY MEANS OF AN ADAPTED ACTIVE REGION Rodenstock GmbH (DE) 2025-07-23 EP claimed
CN-119998352-A Epoxy resin curing agent, epoxy resin composition, sealing material, electrically conductive material, thermally conductive material, adhesive for camera module, adhesive for structure, matrix resin for fiber-reinforced plastic, impregnating and fixing material, interlayer insulating film, film-type solder resist, sealing sheet, electrically conductive film, anisotropic electrically conductive film, thermally conductive film, and method for producing dyed cured product 旭化成株式会社 2025-05-13 CN claimed
US-20250149116-A1 ABL1 FUSIONS AND USES THEREOF FOUNDATION MEDICINE, INC. (US) 2025-05-08 US claimed
CN-119521616-A Energy-saving temperature and humidity regulating air conditioner and regulating method 浙江大观自动化科技有限公司 2025-02-25 CN claimed
WO-2024223632-A1 REDUCING THE PROGRESSION OF MYOPIA BY MEANS OF AN ADAPTED ACTIVE REGION RODENSTOCK GMBH (DE) 2024-10-31 WO claimed
WO-2024223645-A1 SPECTACLE LENS FOR MANAGING MYOPIA BY MEANS OF A DUAL PROGRESSION CONTROL PROCESS RODENSTOCK GMBH (DE) 2024-10-31 WO claimed
WO-2024163952-A2 IDENTIFICATION OF NOVEL SAFE HARBOR SITES FOR THE STABLE EXPRESSION OF FUSOGEN LENTIVIRAL VECTOR SANA BIOTECHNOLOGY, INC. (US) 2024-08-08 WO claimed
EP-0341745-B1 Crosslinked carboxy polysaccharides FIDIA SPA (IT) 1994-12-14 EP claimed
EP-0220030-B1 ORAL DELIVERY SYSTEM BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) 1991-06-19 EP claimed
EP-0122151-B1 PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE MEITO SANGYO KABUSHIKI KAISHA (JP) 1989-02-15 EP claimed
US-4783402-A Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique MEITO SANGYO KABUSHIKI KAISHA (JP) 1988-11-08 US claimed
US-4722938-A COMBINED WITH NON-STEROIDAL ANTIINFLAMMATORY DRUG ANALGESIC ASSOCIATES (US) 1988-02-02 US claimed
EP-0220030-A2 Oral delivery system BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) 1987-04-29 EP claimed
WO-1987002251-A1 ORAL DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES BOUND TO VITAMIN B12, OR ANALOGUES THEREOF BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) 1987-04-23 WO claimed
EP-0205492-A1 ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS SUNSHINE, Abraham (US) 1986-12-30 EP claimed
WO-1986003681-A1 ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS SUNSHINE ABRAHAM 1986-07-03 WO claimed
EP-0122151-A2 Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique MEITO SANGYO KABUSHIKI KAISHA (JP) 1984-10-17 EP claimed